Health & Fitness
Fri, April 20, 2012
SAN DIEGO--([ BUSINESS WIRE ])--ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the 19th Annual Future Leaders in the Biotech Industry Conference on Friday, April 20, 2012, at 11:00 a.m. Eastern Time at the Millennium Broadway Hotel in New York City.
A live webcast of ACADIAas presentation will be accessible on the companyas website, [ www.acadia-pharm.com ], under the investors section and an archived recording will be available on the website through May 4, 2012.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders. ACADIA has four product candidates in clinical development led by pimavanserin, which is in Phase III development as a potential first-in-class treatment for Parkinson's disease psychosis. ACADIAas other clinical-stage products include collaborative programs for chronic pain and glaucoma with Allergan, Inc. and a collaborative program for schizophrenia with Meiji Seika Pharma Co., Ltd. In addition, ACADIA has preclinical programs directed at Parkinsonas disease and other neurological disorders. All of ACADIAas product candidates are small molecules that emanate from discoveries made using its proprietary drug discovery platform. ACADIA maintains a website at [ www.acadia-pharm.com ] to which ACADIA regularly posts copies of its press releases as well as additional information and through which interested parties can subscribe to receive email alerts.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements include but are not limited to statements related to the progress and timing of ACADIAas drug discovery and development programs either alone or with a partner, including clinical trials, and the benefits to be derived from ACADIAas product candidates, in each case including pimavanserin. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug discovery, development and commercialization, and collaborations with others, and the fact that past results of clinical trials may not be indicative of future trial results. For a discussion of these and other factors, please refer to ACADIAas annual report on Form 10-K for the year ended December31, 2011 as well as other subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and ACADIA undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.
